Patents by Inventor Terence A. Potter

Terence A. Potter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gene therapy for effector cell regulation
    Publication number: 20030202962
    Abstract: The present invention provides a nucleic acid-based therapeutic composition to treat an animal with disease by controlling the activity of effector cells, including T cells, macrophages, monocytes and/or natural killer cells, in the animal. Therapeutic compositions of the present invention include superantigen-encoding nucleic acid molecules, either in the presence or absence of a cytokine-encoding nucleic acid molecule and/or chemokine-encoding nucleic acid molecules, depending upon the disease being treated. The present invention also relates to an adjuvant for use with nucleic acid-based vaccines. Adjuvant compositions of the present invention include an immunogen combined with superantigen-encoding nucleic acid molecules, either in the presence or absence of a cytokine-encoding nucleic acid molecule and/or chemokine-encoding nucleic acid molecules.
    Type: Application
    Filed: January 29, 2003
    Publication date: October 30, 2003
    Applicant: National Jewish Medical and Research Center
    Inventors: Steve W. Dow, Robyn E. Elmslie, Terence A. Potter
  • Gene therapy for effector cell regulation
    Patent number: 5935568
    Abstract: The present invention provides a nucleic acid-based therapeutic composition to treat an animal with disease by controlling the activity of effector cells, including T cells, macrophages, monocytes and/or natural killer cells, in the animal. Therapeutic compositions of the present invention include superantigen-encoding nucleic acid molecules, either in the presence or absence of a cytokine-encoding nucleic acid molecule and/or chemokine-encoding nucleic acid molecules, depending upon the disease being treated. The present invention also relates to an adjuvant for use with nucleic acid-based vaccines. Adjuvant compositions of the present invention include an immunogen combined with superantigen-encoding nucleic acid molecules, either in the presence or absence of a cytokine-encoding nucleic acid molecule and/or chemokine-encoding nucleic acid molecules.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: August 10, 1999
    Assignee: National Jewish Medical & Research Center
    Inventors: Steve W. Dow, Robyn E. Elmslie, Terence A. Potter